This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Susan B. Waltzman, PhD; Jay S. Cooper, MD

Arch Otolaryngol. 1981;107(1):52-54.

Abstract
• Misonidazole, a potent new antitumor agent that selectively increases the effect of ionizing radiations on poorly oxygennated tumor cells, was given to 21 patients at New York University-Bellevue Medical Center. In 11 of the 21 patients, hearing loss developed secondary to drug ingestion. In all cases the hearing loss was sensorineural, of cochlear origin, and at least partially reversible. There did not seem to be a relationship between degree of hearing loss and age, sex, dose, anatomic site of lesion, or prior hearing loss.

(Arch Otolaryngol 107:52-54, 1981)

Author Affiliations
From the Departments of Otolaryngology (Dr Waltzman) and Radiology (Radiation Oncology) (Dr Cooper), New York University Medical Center.

Footnotes
Accepted for publication April 2, 1980.

Reprint requests to Department of Otolaryngology, New York University Medical Center, 462 First Ave, New York, NY 10016 (Dr Waltzman).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?